LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; Frankfurt Stock Exchange: LAM; Berlin: LAM), www.lampharm.com/ is pleased to announce that a notice of allowance for a new patent titled "Drug Preparations" has been received by the Company from the United States Patent Office.
This new patent brings to 10 the total number of patents currently held by LAM Pharmaceutical, Corp. for its novel and proprietary Wound Healing and Drug Delivery technology. All 10 patents are currently filed, or will be filed in the near future, on a global basis. LAM management considers the new patent a significant event for the Company because of the patent's scope and specific relevance to LAM's IPM (Ionic Polymer Matrix) technology.
Alan Drizen, CEO and Chief Scientific Officer, said, "The new patent, which has a life of twenty years, ties all of our intellectual property assets together. The protection for the anticipated commercialization, of LAM IPM(TM) Wound Gel, and the other products in our portfolio, is substantially enhanced by the new patent which will be published in the Federal Register in the near future."
Furthermore LAM Pharmaceutical, Corp.'s senior management believes that the current intellectual property estate of the Company would dignify that of many publicly traded pharmaceutical and bio-medical companies with capitalizations in excess of one hundred million dollars.
LAM Pharmaceutical, Corp. is expecting a decision from the FDA on or about April 30, 2002, regarding the marketing of its 510(K) device, LAM IPM(TM) Wound Gel. *
About LAM Pharmaceutical, Corp.
LAM Pharmaceutical, Corp. is a biomedical company with laboratories in Lewiston, New York, and a business office in Toronto. LAM focuses on the development and commercialization of novel wound healing and transdermal drug delivery systems that offer patients, among other benefits, safer and more effective treatment for a variety of serious diseases. The technology is based on an original Ionic Polymer Matrix(TM) technology (IPM(TM)), a proprietary and patented combination (a total of ten U.S. issued and approved patents) of electrically charged and non-charged molecules with wound-healing properties. IPM(TM) technology is also appropriate for use with well-established drugs, allowing for the sustained delivery of greater amounts to the target areas than is otherwise possible by oral means, thus prolonging therapeutic activity.
The main ingredient of the Ionic Polymer Matrix(TM) technology is a derivative of hyaluronic acid, a molecule normally found in the skin, joints and bones. Hyaluronic acid is a non-immunogenic (the body does not react to it) and it is involved in such important biological functions as tissue hydration and proteoglycan organization (formation of proteins and sugars) to optimize tissue repair and prevent tissue aging. As well, hyaluronic acid is present in high concentrations in fetal skin where wound healing is rapid and leaves little scarring.
* LAM IPM(TM) Wound Gel is a clear, viscous, aqueous, odorless gel composed principally of sodium hyaluronate, a derivative salt of Hyaluronic acid. LAM IPM(TM) Wound Gel has demonstrated in both human and animal trials to be of significant value in the management of certain skin ulcers and wounds where maintaining a moist environment is supportive of the healing process. In human skin, Hyaluronic acid is involved in such important biological functions as tissue hydration and proteoglycan organization (formation of proteins and sugars).
As of April 1, 2002, LAM had ten issued and allowed patents in the United States. LAM IPM(TM) Wound Gel is protected by one or more of the following patents: 5,887,880; 6,120,804; 6,007,843; 6,063,405. All referenced patents have been issued to LAM Pharmaceutical, Corp. by the United States Patent Office and have subsequently been filed on a global basis or are in the process of global filing.
The Company's list of products under development include the following:
LAM IPM(TM) - Post Surgical Gel - An advanced IPM(TM) (ionic polymer matrix) designed for use on fresh surgical wounds (stapled or sutured) for the purpose of creating an environment conducive to improved healing.
LAM IPM(TM) - Extreme Dry Skin Formula - A gel formula designed to saturate the stratum corneum, to relieve the symptoms of eczema, dermatitis and extremely dry skin.
LAM IPM(TM) - Female Sexual Dysfunction Matrix - a product that provides enhanced lubrication while also allowing the external structures of the female genitalia to be flushed with greater blood supply.
LAM IPM(TM) - Motion Sickness Matrix - a product currently under development, which is a topically applied delivery system, using a patch, of a well-known motion sickness drug.
LAM IPM(TM) - Arthritic Pain Matrix - is a clear aqueous gel that contains a well proven off patent drug.
For more information please visit our website at www.lampharm.com or send us an e-mail at info@lampharm.com to receive the latest information and press releases.
Company Contact: Anthony Vespa Toll Free in N. America (877) LAM-7717 (877) 526-7717 Tel (416) 633-7047 Fax (416) 633-2363 Website: www.lampharm.com Press Contact: Barry S. Kaplan (732) 747-0702 FAX (732) 758-1837 Email: smallkap@aol.com
Statements in this press release regarding our business which are not historical facts are "forward-looking statements" that involve risks and uncertainties which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.
LAM Pharmaceutical, Corp.
© PR Newswire
This new patent brings to 10 the total number of patents currently held by LAM Pharmaceutical, Corp. for its novel and proprietary Wound Healing and Drug Delivery technology. All 10 patents are currently filed, or will be filed in the near future, on a global basis. LAM management considers the new patent a significant event for the Company because of the patent's scope and specific relevance to LAM's IPM (Ionic Polymer Matrix) technology.
Alan Drizen, CEO and Chief Scientific Officer, said, "The new patent, which has a life of twenty years, ties all of our intellectual property assets together. The protection for the anticipated commercialization, of LAM IPM(TM) Wound Gel, and the other products in our portfolio, is substantially enhanced by the new patent which will be published in the Federal Register in the near future."
Furthermore LAM Pharmaceutical, Corp.'s senior management believes that the current intellectual property estate of the Company would dignify that of many publicly traded pharmaceutical and bio-medical companies with capitalizations in excess of one hundred million dollars.
LAM Pharmaceutical, Corp. is expecting a decision from the FDA on or about April 30, 2002, regarding the marketing of its 510(K) device, LAM IPM(TM) Wound Gel. *
About LAM Pharmaceutical, Corp.
LAM Pharmaceutical, Corp. is a biomedical company with laboratories in Lewiston, New York, and a business office in Toronto. LAM focuses on the development and commercialization of novel wound healing and transdermal drug delivery systems that offer patients, among other benefits, safer and more effective treatment for a variety of serious diseases. The technology is based on an original Ionic Polymer Matrix(TM) technology (IPM(TM)), a proprietary and patented combination (a total of ten U.S. issued and approved patents) of electrically charged and non-charged molecules with wound-healing properties. IPM(TM) technology is also appropriate for use with well-established drugs, allowing for the sustained delivery of greater amounts to the target areas than is otherwise possible by oral means, thus prolonging therapeutic activity.
The main ingredient of the Ionic Polymer Matrix(TM) technology is a derivative of hyaluronic acid, a molecule normally found in the skin, joints and bones. Hyaluronic acid is a non-immunogenic (the body does not react to it) and it is involved in such important biological functions as tissue hydration and proteoglycan organization (formation of proteins and sugars) to optimize tissue repair and prevent tissue aging. As well, hyaluronic acid is present in high concentrations in fetal skin where wound healing is rapid and leaves little scarring.
* LAM IPM(TM) Wound Gel is a clear, viscous, aqueous, odorless gel composed principally of sodium hyaluronate, a derivative salt of Hyaluronic acid. LAM IPM(TM) Wound Gel has demonstrated in both human and animal trials to be of significant value in the management of certain skin ulcers and wounds where maintaining a moist environment is supportive of the healing process. In human skin, Hyaluronic acid is involved in such important biological functions as tissue hydration and proteoglycan organization (formation of proteins and sugars).
As of April 1, 2002, LAM had ten issued and allowed patents in the United States. LAM IPM(TM) Wound Gel is protected by one or more of the following patents: 5,887,880; 6,120,804; 6,007,843; 6,063,405. All referenced patents have been issued to LAM Pharmaceutical, Corp. by the United States Patent Office and have subsequently been filed on a global basis or are in the process of global filing.
The Company's list of products under development include the following:
LAM IPM(TM) - Post Surgical Gel - An advanced IPM(TM) (ionic polymer matrix) designed for use on fresh surgical wounds (stapled or sutured) for the purpose of creating an environment conducive to improved healing.
LAM IPM(TM) - Extreme Dry Skin Formula - A gel formula designed to saturate the stratum corneum, to relieve the symptoms of eczema, dermatitis and extremely dry skin.
LAM IPM(TM) - Female Sexual Dysfunction Matrix - a product that provides enhanced lubrication while also allowing the external structures of the female genitalia to be flushed with greater blood supply.
LAM IPM(TM) - Motion Sickness Matrix - a product currently under development, which is a topically applied delivery system, using a patch, of a well-known motion sickness drug.
LAM IPM(TM) - Arthritic Pain Matrix - is a clear aqueous gel that contains a well proven off patent drug.
For more information please visit our website at www.lampharm.com or send us an e-mail at info@lampharm.com to receive the latest information and press releases.
Company Contact: Anthony Vespa Toll Free in N. America (877) LAM-7717 (877) 526-7717 Tel (416) 633-7047 Fax (416) 633-2363 Website: www.lampharm.com Press Contact: Barry S. Kaplan (732) 747-0702 FAX (732) 758-1837 Email: smallkap@aol.com
Statements in this press release regarding our business which are not historical facts are "forward-looking statements" that involve risks and uncertainties which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.
LAM Pharmaceutical, Corp.
© PR Newswire
